Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05357521
Other study ID # 2002-00067
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 1, 2022
Est. completion date April 30, 2022

Study information

Verified date June 2022
Source University of Geneva, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to determine the feasibility and preliminary data on the interaction between oxytocin and cortisol during stress in borderline personnality disorder.


Description:

The investigators will recruit 10 female patients with borderline personnality disorder and 10 controls with no psychiatric diagnosis, aged between 18 and 25 years old. salivary cortisol daily curve ( 6 measures during the day) will be measured in participant's naturalistic environnement, together with salivary oxytocin. In addition, salivary oxytocin and cortisol will be measured during a psychosocial stress task and recovery.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date April 30, 2022
Est. primary completion date April 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 25 Years
Eligibility Inclusion Criteria: - Borderline personality disorder-DSM V Exclusion Criteria: - Schizophrenia

Study Design


Intervention

Other:
stress test
TSST- psychosocial stress test

Locations

Country Name City State
Switzerland Young Adult Psychiatric Unit Geneva

Sponsors (1)

Lead Sponsor Collaborator
University of Geneva, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Salivary cortisol salivary cortisol measured with salivettes (swabs) Baseline
Primary Salivary cortisol salivary cortisol measured with salivettes (swabs) Change in one day (circadian cortisol with 6 measures within one day
Primary Salivary cortisol salivary cortisol measured with salivettes (swabs) Change during experimental task (up to 2 hours)
Primary Salivary oxytocin salivary oxytocin measured with salivettes (swabs) Baseline
Primary Salivary oxytocin salivary oxytocin measured with salivettes (swabs) Two measures within one day
Primary Salivary oxytocin salivary oxytocin measured with salivettes (swabs) Change during experimental task (up to 2 hours)
See also
  Status Clinical Trial Phase
Recruiting NCT04856449 - DBT Skills Plus EMDR for BPD and Trauma N/A
Active, not recruiting NCT04587518 - Five Factor Model Treatment for Borderline Personality Disorder N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Completed NCT03677037 - The Short-Term MBT Project Phase 3
Not yet recruiting NCT05989529 - Delving Into Borderline Personality Disorder Clinical Trial Experiences
Completed NCT02518906 - Evaluation of AIT Study N/A
Completed NCT02068326 - MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial N/A
Recruiting NCT04296604 - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations N/A
Terminated NCT02149823 - Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Phase 1
Completed NCT02108990 - Acetaminophen and Social Processes Phase 2
Not yet recruiting NCT01683136 - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder N/A
Completed NCT01635556 - Evaluation of a Modified Dialectical Behavior Therapy Program N/A
Completed NCT02988037 - Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study N/A
Completed NCT02397031 - Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder N/A
Terminated NCT01212588 - Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) Phase 2
Terminated NCT01103180 - Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder Phase 2
Terminated NCT00539188 - N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD Phase 2
Recruiting NCT05398627 - Neurofeedback for Borderline Personality Disorder N/A
Recruiting NCT03994510 - SHame prOpensity in bOrderline Personality Disorder N/A
Recruiting NCT06005129 - Personality Change Study for Borderline Personality Disorder N/A